AmpliPhi Biosciences Corporation is a biotechnology company that focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. It is also developing targeted and personalized bacteriophage therapies for patients with serious or life-threatening antibiotic-resistant infections. The company is working on products for the treatment of Staphylococcus aureus and pseudomonas aeruginosa lung infections. AmpliPhi Biosciences merged with C3J Therapeutics to form Armata Pharmaceuticals.